Russia enters final stage of clinical trial of drug to treat Covid patients

Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group on Friday introduced the beginning of the ultimate stage of the multicenter randomized open comparative medical trial of the drug Favipiravir on sufferers hospitalized with COVID-19.

On 21 May, the Ministry of Health of the Russian Federation authorised the launch of the ultimate stage, which is able to contain 330 sufferers in comparison with 60 through the preliminary stage, in addition to further analysis and medical facilities. In whole, 30 medical facilities in 9 Russian areas will conduct research on the remaining stage.

The first stage of the trials has already been accomplished. It lasted 10 days and concerned 60 sufferers with coronavirus infection with reasonable sickness. Forty individuals obtained Favipiravir therapy and the opposite 20 sufferers from the management group have been on customary remedy. According to the outcomes of the primary stage, Favipiravir demonstrated security with no new or beforehand unreported unwanted side effects detected. The drug’s efficacy was above a threshold of 80%, which is the criterion for a drug with excessive antiviral exercise. The physique temperature of 68% of sufferers taking Favipiravir returned to regular earlier (on the third day) than within the management group (on the sixth day). On common, full elimination of the virus from the physique on account of Favipiravir therapy occurred in 4 days, whereas in the usual remedy group this course of took 9 days.

Following the primary 4 days of therapy, 65% of the 40 sufferers who took Favipiravir examined unfavourable for coronavirus, which is twice as many as in the usual remedy group. By day 10, the variety of sufferers whose checks returned unfavourable outcomes reached 35 out of 40.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, stated, “We continue to receive promising data during the clinical trials of Favipiravir. At least 85% of patients in the control groups completely recovered from coronavirus within 10 days after the start of the treatment with the drug. We expect a positive final result of the trial, which will enable us to complete the registration procedure for the drug in Russia and roll out full-scale production and delivery to medical institutions across the country.”

“We noticed a faster improvement in the general health and clinical condition of the patients taking Favipiravir, which may lead to earlier discharge from hospital and reduce the burden on medical facilities by 30-40% in the near future. Thanks to the administration of Favipiravir, most patients are not infectious as early as the fifth day of treatment, which is critical to stop the epidemic and ensure a swift return to normal life,” stated Elena Yakubova, CEO of ChemRar Pharma.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *